Salvia BioElectronics
Clinical-stage medical device company developing an investigational bioelectronic neuromodulation therapy for chronic migraine based on ultra-thin subcutaneous implants and an external wearable activator. Activities include multi-center randomized clinical trials, device verification and validation, regulatory interactions (including a Breakthrough Device designation), participation in collaborative R&D projects for flexible electronics and preparations for scale-up and commercialization.
Industries
Nr. of Employees
small (1-50)
Salvia BioElectronics
High Tech Campus 37, 5656 AE Eindhoven, The Netherlands
Patents
Products
Investigational subcutaneous neuromodulation therapy
An investigational therapy consisting of two ultra-thin subcutaneous implants (forehead and back of head) and an external wearable activator enabling targeted, user-initiated electrical stimulation for chronic migraine; currently in clinical evaluation.
Investigational subcutaneous neuromodulation therapy
An investigational therapy consisting of two ultra-thin subcutaneous implants (forehead and back of head) and an external wearable activator enabling targeted, user-initiated electrical stimulation for chronic migraine; currently in clinical evaluation.
Services
Design and conduct of randomized, sham-controlled, multi-center clinical studies in collaboration with hospital investigators; site coordination and clinical operations support.
Participation and technical contribution to multi-partner R&D consortia focused on flexible electronics, wearable patches and scalable manufacturing techniques.
Design and conduct of randomized, sham-controlled, multi-center clinical studies in collaboration with hospital investigators; site coordination and clinical operations support.
Participation and technical contribution to multi-partner R&D consortia focused on flexible electronics, wearable patches and scalable manufacturing techniques.
Expertise Areas
- Neuromodulation therapy development
- Flexible bioelectronic materials and foil implants
- Clinical trial management for implantable devices
- Regulatory strategy and submissions (US, EU, Australia)
Key Technologies
- Neuromodulation
- Ultra-thin bioelectronic foil implants
- Flexible interconnects and planar hybrid foil systems
- Roll-to-roll (R2R) flexible electronics processing
News & Updates
Raised $60 million (€53 million) in a Series B round to fund completion of clinical development and commercial launch preparations, and regulatory submissions in the US, Europe and Australia.
First Dutch patient received the investigational ultra-thin migraine implant as part of a multi-center clinical study (RECLAIM) performed at Erasmus MC; study also includes additional European and Australian sites.
Selected to participate in the MedTech Innovator 2024 Accelerator cohort following a competitive selection process.
Received blended funding award from the European Innovation Council to support clinical development for a complementary cluster headache indication.
Raised $60 million (€53 million) in a Series B round to fund completion of clinical development and commercial launch preparations, and regulatory submissions in the US, Europe and Australia.
First Dutch patient received the investigational ultra-thin migraine implant as part of a multi-center clinical study (RECLAIM) performed at Erasmus MC; study also includes additional European and Australian sites.
Selected to participate in the MedTech Innovator 2024 Accelerator cohort following a competitive selection process.
Received blended funding award from the European Innovation Council to support clinical development for a complementary cluster headache indication.